• Rigel Pharmaceuticals Inc., of South San Francisco, reported that two of its lead candidates have entered Phase I trials. R548, an oral JAK3 inhibitor, is being evaluated for transplant rejection and other systemic immune disorders. R333, a topical JAK/SYK inhibitor, is aimed at treating various phases of discoid lupus.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter